NEUROENDOCRINE CARCINOMA
Clinical trials for NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus plus immunotherapy: new hope for rare neuroendocrine cancers?
Disease control Recruiting nowThis early-phase trial tests a virus that targets and kills cancer cells (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
New drug combo aims to shrink tough lung cancers
Disease control Recruiting nowThis study tests whether combining two experimental drugs, ZG006 and ZG005, can shrink tumors in people with advanced small cell lung cancer or neuroendocrine carcinoma. About 350 adults aged 18 to 70 will take part. The goal is to see if the combination is safe and works better …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New hope for tough cancers: ZG006 trial opens for patients out of options
Disease control Recruiting nowThis study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 will take pa…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Gene-Guided drug dosing could improve treatment for rare cancer
Disease control Recruiting nowThis study aims to find the best dose of the drug belinostat for people with high-grade neuroendocrine carcinomas based on their genetic makeup. Some people have a gene variant that affects how quickly their body processes belinostat, so adjusting the dose may reduce side effects…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Immunotherapy shows promise for rare cancers in new trial
Disease control Recruiting nowThis study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for rare cancer: chemo showdown aims to extend lives
Disease control Recruiting nowThis study tests whether a chemotherapy combination called FOLFIRINOX works better than the standard platinum-etoposide regimen for people with advanced, aggressive neuroendocrine cancer of the digestive system or unknown origin. About 218 participants will receive one of the two…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for rare cancer: tarlatamab takes on chemo in advanced NEC
Disease control Recruiting nowThis phase 3 trial tests whether tarlatamab works better than standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC) that has already been treated. About 129 adults with lung or digestive system NEC will receive either tarlatamab or chemo chosen by their do…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New pill takes on Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Lung cancer study aims to match patients to precision treatments
Knowledge-focused Recruiting nowThis study screens up to 797 people with relapsed small cell lung cancer to identify genetic changes in their tumors. Researchers use tissue and blood samples to look for specific markers that could make them eligible for future targeted therapy trials. No experimental drugs are …
Matched conditions: NEUROENDOCRINE CARCINOMA
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated May 07, 2026 18:39 UTC